A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 43 sites in 3 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 16th largest by enrollment, is one of 3 that started in 2022, is one of 14 in phase 3, and was the 11th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2022.
This study's enrollment of 356 is close to the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 40th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2022, is one of 33 in phase 3, and was the 58th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13.
This study is being conducted in children who:
Participants in this study will receive either 1 dose or 2 doses of the study vaccine or 1 dose of Prevnar 13 as a shot in the muscle. During the study, participants will have to come to the study clinic to receive the vaccines and have blood sample collected. The study team will work with participants' parents or legal guardians to monitor any unwanted reactions to the vaccines. Participants are expected to take part in this study for about 1 or 3 months, for 1 dose or 2 dose schedules, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccine (2 doses approximately 2 months apart)
Biological: 20-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination
Local reactions included redness, swelling, and pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
Time frame: Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Percentage of Participants With Systemic Events Within 7 Days After Last Vaccination
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
Time frame: Within 7 days after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Percentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. 95% CI was based on the Clopper and Pearson method. AEs reported in this endpoint excluded local reactions and systemic events collected from an e-diary.
Time frame: From last vaccination to 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Percentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination
A SAE was any untoward medical occurrence that: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, was considered serious and other important medical events. 95% CI was based on the Clopper and Pearson method.
Time frame: From last vaccination to 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Percentage of Participants With Predefined Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes 1 Month After Last Vaccination
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. The predefined level was 0.35 microgram per milliliter (mcg/mL) for all 7 additional serotypes. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Serotype-specific IgG Geometric Mean Concentrations (GMC) 1 Month After Last Vaccination
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution).
Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Percentage of Participants With Predefined IgG Concentrations for the 13 Matched Serotypes 1 Month After Last Vaccination
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes:1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,19A,19F, 23F. Predefined level was 0.35 mcg/mL for all 13vPnC serotypes except serotypes 5, 6B, and 19A, which had predefined levels of 0.23, 0.10, and 0.12 mcg/mL, respectively. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Last Vaccination
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after last vaccination received. OPA titers below the LLOQ were set to 0.5\*LLOQ. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.
Time frame: 1 Month after last vaccination (for reporting arm 2-Dose 20vPnC last vaccination was Dose 2 and for 1-dose 20vPnC and 13vPnC Control it was Dose 1)
Participants included in this study were toddlers greater than or equal to (\>=) 12 to less than (\<) 24 months of age who had received 2 doses of 13-valent pneumococcal conjugate vaccine (13vPnC) (Prevenar 13) in infancy (prior to 12 months of age).
| Milestone | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Started | 121 | 118 | 117 |
| Completed | 115 | 117 | 116 |
| Not completed | 6 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 | 1 |
Local reactions included redness, swelling, and pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
| Percentage of participants | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Redness: Any | 26.3 ± 18.5 | 29.7 ± 21.6 | 32.5 ± 24.1 |
| Redness: Mild | 13.2 ± 7.6 | 18.6 ± 12.1 | 17.9 ± 11.5 |
| Redness: Moderate | 12.3 ± 6.9 | 11.0 ± 6.0 | 14.5 ± 8.7 |
| Redness: Severe | 0.9 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 23.7 ± 16.2 | 21.2 ± 14.2 | 25.6 ± 18.0 |
| Swelling: Mild | 14.0 ± 8.2 | 12.7 ± 7.3 | 16.2 ± 10.1 |
| Swelling: Moderate | 8.8 ± 4.3 | 8.5 ± 4.1 | 9.4 ± 4.8 |
| Swelling: Severe | 0.9 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at Injection Site: Any | 29.8 ± 21.6 | 28.8 ± 20.8 | 31.6 ± 23.3 |
| Pain at Injection Site: Mild | 17.5 ± 11.1 | 17.8 ± 11.4 | 26.5 ± 18.8 |
| Pain at Injection Site: Moderate | 12.3 ± 6.9 | 11.0 ± 6.0 | 5.1 ± 1.9 |
| Pain at Injection Site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
| Percentage of participants | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Fever: >=38.0 degrees C | 9.6 ± 4.9 | 15.3 ± 9.3 | 15.4 ± 9.4 |
| Fever: >38.0 degrees C to 38.4 degrees C | 3.5 ± 1.0 | 6.8 ± 3.0 | 10.3 ± 5.4 |
| Fever: >38.4 degrees C to 38.9 degrees C | 4.4 ± 1.4 | 3.4 ± 0.9 | 2.6 ± 0.5 |
| Fever: >38.9 degrees C to 40.0 degrees C | 1.8 ± 0.2 | 5.1 ± 1.9 | 2.6 ± 0.5 |
| Fever: >40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Any | 25.4 ± 17.7 | 33.1 ± 24.7 | 26.5 ± 18.8 |
| Decreased appetite: Mild | 14.9 ± 8.9 | 15.3 ± 9.3 | 12.0 ± 6.7 |
| Decreased appetite: Moderate | 10.5 ± 5.6 | 14.4 ± 8.6 | 13.7 ± 8.0 |
| Decreased appetite: Severe | 0 ± 0.0 | 3.4 ± 0.9 | 0.9 ± 0.0 |
| Drowsiness/increased sleep: Any | 23.7 ± 16.2 | 32.2 ± 23.9 | 31.6 ± 23.3 |
| Drowsiness/increased sleep: Mild | 18.4 ± 11.8 | 25.4 ± 17.9 | 21.4 ± 14.3 |
| Drowsiness/increased sleep: Moderate | 5.3 ± 2.0 | 5.9 ± 2.4 | 10.3 ± 5.4 |
| Drowsiness/increased sleep: Severe | 0 ± 0.0 | 0.8 ± 0.0 | 0 ± 0.0 |
| Irritability: Any | 55.3 ± 45.7 | 50.8 ± 41.5 | 46.2 ± 36.9 |
| Irritability: Mild | 24.6 ± 17.0 | 15.3 ± 9.3 | 16.2 ± 10.1 |
| Irritability: Moderate | 29.8 ± 21.6 | 32.2 ± 23.9 | 29.9 ± 21.8 |
| Irritability: Severe | 0.9 ± 0.0 | 3.4 ± 0.9 | 0 ± 0.0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. 95% CI was based on the Clopper and Pearson method. AEs reported in this endpoint excluded local reactions and systemic events collected from an e-diary.
| Percentage of participants | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination | 22.4 ± 15.2 | 24.6 ± 17.1 | 25.6 ± 18.0 |
A SAE was any untoward medical occurrence that: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, was considered serious and other important medical events. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination | 0.9 ± 0.0 | 0.8 ± 0.0 | 0.9 ± 0.0 |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. The predefined level was 0.35 microgram per milliliter (mcg/mL) for all 7 additional serotypes. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Serotype 8 | 100.0 (96.4 to 100.0) | 98.1 (93.5 to 99.8) | 8.4 (3.9 to 15.4) |
| Serotype 10A | 99.0 (94.7 to 100.0) | 87.0 (79.2 to 92.7) | 1.9 (0.2 to 6.5) |
| Serotype 11A | 99.0 (94.7 to 100.0) | 96.3 (90.8 to 99.0) | 13.0 (7.3 to 20.8) |
| Serotype 12F | 91.2 (83.9 to 95.9) | 54.6 (44.8 to 64.2) | 0.0 (0.0 to 3.4) |
| Serotype 15B | 100.0 (96.4 to 100.0) | 75.9 (66.7 to 83.6) | 6.5 (2.6 to 12.9) |
| Serotype 22F | 100.0 (96.4 to 100.0) | 94.4 (88.3 to 97.9) | 2.8 (0.6 to 7.9) |
| Serotype 33F | 99.0 (94.7 to 100.0) | 83.3 (74.9 to 89.8) | 3.7 (1.0 to 9.2) |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution).
| mcg/mL | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Serotype 1 | 1.66 (1.39 to 2.00) | 2.40 (1.95 to 2.96) | 3.38 (2.82 to 4.05) |
| Serotype 3 | 0.78 (0.65 to 0.93) | 0.95 (0.80 to 1.14) | 1.24 (1.06 to 1.45) |
| Serotype 4 | 3.09 (2.63 to 3.63) | 4.54 (3.63 to 5.67) | 5.67 (4.81 to 6.70) |
| Serotype 5 | 1.61 (1.36 to 1.92) | 2.03 (1.64 to 2.51) | 2.46 (2.04 to 2.95) |
| Serotype 6A | 8.55 (7.25 to 10.07) | 12.45 (10.16 to 15.27) | 16.28 (13.48 to 19.66) |
| Serotype 6B | 5.17 (4.25 to 6.29) | 4.87 (3.60 to 6.60) | 6.64 (5.19 to 8.52) |
| Serotype 7F | 4.78 (4.15 to 5.49) | 4.41 (3.81 to 5.10) | 6.32 (5.49 to 7.28) |
| Serotype 9V | 3.44 (2.96 to 3.99) | 3.94 (3.29 to 4.71) | 5.36 (4.55 to 6.31) |
| Serotype 14 | 5.58 (4.66 to 6.68) | 7.37 (5.85 to 9.29) | 8.64 (7.01 to 10.64) |
| Serotype 18C | 2.84 (2.39 to 3.39) | 3.13 (2.62 to 3.74) | 3.78 (3.14 to 4.54) |
| Serotype 19A | 3.31 (2.80 to 3.90) | 6.36 (5.22 to 7.74) | 6.89 (5.76 to 8.23) |
| Serotype 19F | 5.25 (4.38 to 6.28) | 8.78 (7.04 to 10.94) | 10.09 (8.33 to 12.22) |
| Serotype 23F | 5.06 (4.23 to 6.05) | 4.45 (3.58 to 5.53) | 6.32 (5.07 to 7.89) |
| Serotype 8 | 10.16 (8.75 to 11.79) | 7.56 (6.22 to 9.19) | 0.05 (0.04 to 0.07) |
| Serotype 10A | 6.54 (5.17 to 8.28) | 1.32 (0.98 to 1.76) | 0.01 (0.01 to 0.02) |
| Serotype 11A | 4.83 (4.11 to 5.68) | 2.72 (2.17 to 3.41) | 0.03 (0.02 to 0.04) |
| Serotype 12F | 1.72 (1.40 to 2.12) | 0.33 (0.25 to 0.45) | 0.01 (0.01 to 0.01) |
| Serotype 15B | 11.21 (9.39 to 13.38) | 0.95 (0.74 to 1.21) | 0.03 (0.02 to 0.04) |
| Serotype 22F | 15.45 (13.24 to 18.03) | 8.66 (6.27 to 11.98) | 0.01 (0.00 to 0.01) |
| Serotype 33F | 4.94 (4.04 to 6.03) | 1.68 (1.21 to 2.34) | 0.02 (0.01 to 0.02) |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes:1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,19A,19F, 23F. Predefined level was 0.35 mcg/mL for all 13vPnC serotypes except serotypes 5, 6B, and 19A, which had predefined levels of 0.23, 0.10, and 0.12 mcg/mL, respectively. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Serotype 1 | 94.1 (87.6 to 97.8) | 94.4 (88.3 to 97.9) | 98.1 (93.5 to 99.8) |
| Serotype 3 | 88.2 (80.4 to 93.8) | 87.0 (79.2 to 92.7) | 93.5 (87.1 to 97.4) |
| Serotype 4 | 98.0 (93.1 to 99.8) | 99.1 (94.9 to 100.0) | 100.0 (96.6 to 100.0) |
| Serotype 5 | 97.1 (91.6 to 99.4) | 96.3 (90.8 to 99.0) | 100.0 (96.6 to 100.0) |
| Serotype 6A | 100.0 (96.4 to 100.0) | 99.1 (94.9 to 100.0) | 99.1 (94.9 to 100.0) |
| Serotype 6B | 100.0 (96.4 to 100.0) | 98.1 (93.5 to 99.8) | 100.0 (96.6 to 100.0) |
| Serotype 7F | 100.0 (96.4 to 100.0) | 100.0 (96.6 to 100.0) | 100.0 (96.6 to 100.0) |
| Serotype 9V | 100.0 (96.4 to 100.0) | 99.1 (94.9 to 100.0) | 100.0 (96.6 to 100.0) |
| Serotype 14 | 100.0 (96.4 to 100.0) | 99.1 (94.9 to 100.0) | 99.1 (94.9 to 100.0) |
| Serotype 18C | 100.0 (96.4 to 100.0) | 98.1 (93.5 to 99.8) | 99.1 (94.9 to 100.0) |
| Serotype 19A | 100.0 (96.4 to 100.0) | 100.0 (96.6 to 100.0) | 100.0 (96.6 to 100.0) |
| Serotype 19F | 100.0 (96.4 to 100.0) | 99.1 (94.9 to 100.0) | 100.0 (96.6 to 100.0) |
| Serotype 23F | 99.0 (94.7 to 100.0) | 99.1 (94.9 to 100.0) | 97.2 (92.1 to 99.4) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after last vaccination received. OPA titers below the LLOQ were set to 0.5\*LLOQ. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.
| Titers | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control |
|---|---|---|---|
| Serotype 1 | 46 (26 to 82) | 79 (47 to 133) | 105 (68 to 162) |
| Serotype 3 | 131 (106 to 163) | 101 (72 to 142) | 128 (93 to 176) |
| Serotype 4 | 348 (178 to 681) | 425 (213 to 845) | 541 (298 to 984) |
| Serotype 5 | 46 (30 to 69) | 77 (52 to 114) | 73 (52 to 104) |
| Serotype 6A | 1470 (1030 to 2096) | 1156 (768 to 1739) | 1796 (1286 to 2508) |
| Serotype 6B | 698 (437 to 1114) | 452 (275 to 743) | 790 (459 to 1357) |
| Serotype 7F | 1415 (844 to 2371) | 1212 (755 to 1945) | 1367 (790 to 2365) |
| Serotype 9V | 1719 (928 to 3185) | 1792 (1015 to 3166) | 1930 (1048 to 3556) |
| Serotype 14 | 844 (474 to 1501) | 1245 (837 to 1852) | 558 (308 to 1011) |
| Serotype 18C | 1861 (1115 to 3106) | 1047 (583 to 1882) | 1149 (684 to 1930) |
| Serotype 19A | 512 (283 to 925) | 731 (401 to 1332) | 973 (560 to 1688) |
| Serotype 19F | 473 (257 to 873) | 470 (285 to 775) | 595 (363 to 975) |
| Serotype 23F | 727 (382 to 1382) | 472 (255 to 876) | 721 (439 to 1186) |
| Serotype 8 | 3446 (2282 to 5203) | 1609 (989 to 2617) | 76 (42 to 137) |
| Serotype 10A | 6783 (4555 to 10100) | 2506 (1425 to 4407) | 64 (40 to 104) |
| Serotype 11A | 3827 (1975 to 7414) | 3416 (1523 to 7665) | 235 (99 to 562) |
| Serotype 12F | 17398 (11121 to 27218) | 7346 (3895 to 13855) | 64 (34 to 122) |
| Serotype 15B | 10024 (6200 to 16206) | 3898 (1867 to 8136) | 58 (24 to 143) |
| Serotype 22F | 11820 (7993 to 17480) | 6117 (3289 to 11376) | 28 (13 to 61) |
| Serotype 33F | 43671 (28126 to 67809) | 15355 (9431 to 24998) | 694 (432 to 1115) |
Collected over Local reactions and systemic events (systematic assessment): Within 7 days after Dose 1 and 2; All-cause mortality, SAEs and non-SAEs (non-systematic assessment): from Dose 1 to 1 month after Dose 1 (1-dose groups) or Dose 2 (2-dose group). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2-Dose 20vPnC (Dose 1 to Dose 2) | 0/121 (0%) | 4/121 (3.3%) | 93/121 (76.9%) |
| 2-Dose 20vPnC (Dose 2 to 1 Month After Dose 2) | 0/116 (0%) | 1/116 (0.9%) | 91/116 (78.4%) |
| 1-Dose 20vPnC (Dose 1 to 1 Month After Dose 1) | 0/118 (0%) | 1/118 (0.8%) | 90/118 (76.3%) |
| 13vPnC Control (Dose 1 to 1 Month After Dose 1) | 0/117 (0%) | 1/117 (0.9%) | 98/117 (83.8%) |
| Event | 2-Dose 20vPnC (Dose 1 to Dose 2) | 2-Dose 20vPnC (Dose 2 to 1 Month After Dose 2) | 1-Dose 20vPnC (Dose 1 to 1 Month After Dose 1) | 13vPnC Control (Dose 1 to 1 Month After Dose 1) |
|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/121 | 1/116 | 0/118 | 0/117 |
| Lower respiratory tract infectionInfections and infestations | 1/121 | 1/116 | 0/118 | 0/117 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/121 | 0/116 | 0/118 | 1/117 |
| Thermal burnInjury, poisoning and procedural complications | 0/121 | 0/116 | 1/118 | 0/117 |
| Febrile convulsionNervous system disorders | 1/121 | 0/116 | 0/118 | 0/117 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/121 | 0/116 | 0/118 | 0/117 |
| BronchitisInfections and infestations | 1/121 | 0/116 | 0/118 | 0/117 |
| GastroenteritisInfections and infestations | 1/121 | 0/116 | 0/118 | 0/117 |
| Event | 2-Dose 20vPnC (Dose 1 to Dose 2) | 2-Dose 20vPnC (Dose 2 to 1 Month After Dose 2) | 1-Dose 20vPnC (Dose 1 to 1 Month After Dose 1) | 13vPnC Control (Dose 1 to 1 Month After Dose 1) |
|---|---|---|---|---|
| IrritabilityPsychiatric disorders | 70/121 | 63/116 | 60/118 | 54/117 |
| Injection site erythema (REDNESS)General disorders | 40/121 | 30/116 | 35/118 | 38/117 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 37/121 | 29/116 | 39/118 | 31/117 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 39/121 | 27/116 | 38/118 | 37/117 |
| Injection site pain (PAIN)General disorders | 33/121 | 34/116 | 34/118 | 37/117 |
| Injection site swelling (SWELLING)General disorders | 27/121 | 27/116 | 25/118 | 30/117 |
| Pyrexia (FEVER)General disorders | 20/121 | 11/116 | 18/118 | 18/117 |
| Upper respiratory tract infectionInfections and infestations | 18/121 | 9/116 | 13/118 | 9/117 |
Safety population included all participants who receive at least 1 dose of the study intervention and have safety data reported after any dose.
| Age, Continuous(months) | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control | Total |
|---|---|---|---|---|
| Mean | 12.5 ± 1.21 | 12.6 ± 1.52 | 12.7 ± 1.85 | 12.6 ± 1.54 |
| Age, Customized(Participants) | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control | Total |
|---|---|---|---|---|
| Infants and toddlers (28 days-23 months) | 121 | 118 | 117 | 356 |
| Sex: Female, Male(Participants) | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control | Total |
|---|---|---|---|---|
| Female | 60 | 47 | 57 | 164 |
| Male | 61 | 71 | 60 | 192 |
| Ethnicity (NIH/OMB)(Participants) | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control | Total |
|---|---|---|---|---|
| Hispanic or Latino | 34 | 36 | 32 | 102 |
| Not Hispanic or Latino | 86 | 82 | 85 | 253 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | 2-Dose 20vPnC | 1-Dose 20vPnC | 13vPnC Control | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 120 | 117 | 113 | 350 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2022 to primary completion in Jun 2023, 11 months.
Results were first posted in Sep 2024, 1 year 3 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 11 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine